Please login to the form below
Avonex
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.
New accounts: January
Biogen. Avonex. Multiple sclerosis. Brader Perryman. Cambridge Laboratories. Gelclair. Oncology/ENT. RFA Advertising.
Double or quits!
Avonex (Biogen Idec) and Rebif (Serono) are recombinant human inter-feron B-1a products; administration is via subcutaneous (SC) injection once- and thrice-weekly, respectively. ... However, Avonex can also be used for a single neurological event
New accounts: February
Biogen. Avonex. Multiple sclerosis. Brader Perryman. Eden Biodesign. N/A. Corporate. Affiniti (UK).
Turbulent times
The companies revealed that one patient had died after taking Tysabri for two years in combination with Avonex while a second was suspected of developing a central nervous system disease.
Biogen Idec board may sell
Biogen's primary drug portfolio consists of multiple sclerosis (MS) drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), as well as rheumatoid arthritis (RA) and cancer drug Rituxan (rituximab).
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Communique - Communiqué Awards
- How will the events and exhibitions industry change post-Coronavirus?
- Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK
- FDA approves Roche’s Actemra COVID-19 trial
- Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
- Finalists 2020 - Communiqué Awards
- Patients are ready for virtual clinical trials, are you?
- Onyx Health Tackles Diabetes with New Client
- Regeneron’s COVID-19 antibody cocktail enters phase 3 trial
- Mesoblast expands compassionate use COVID-19 programme
- EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug
- OPEN Health scoops up Medical Affairs Agency Award at Communiqué 2020
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Patients are ready for virtual clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
- Keep your audiences close
- How getting up close and personal with target audiences can fuel creativity...
- The search for treatments for Parkinson’s disease
- The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Quick links
Infographics
